Checkpoint kinase 1 inhibitors as targeted molecular agents for clear cell carcinoma of the ovary (Review)

Kobayashi,Hiroshi; Shigetomi,Hiroshi; Yoshimoto,Chiharu

doi:10.3892/ol.2015.3268

Checkpoint kinase 1 inhibitors as targeted molecular agents for clear cell carcinoma of the ovary (Review)

Authors:
- Hiroshi Kobayashi
- Hiroshi Shigetomi
- Chiharu Yoshimoto
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Nara 634-8522, Japan
Published online on: May 26, 2015 https://doi.org/10.3892/ol.2015.3268
Pages: 571-576

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In clear cell carcinoma of the ovary, chemoresistance frequently results in treatment failure. The present study aimed to review the potential association of transcription factor hepatocyte nuclear factor (HNF)-1β with cell cycle checkpoint machinery, as a mechanism for chemoresistance. The English-language literature on the subject was reviewed to identify genomic alterations and aberrant molecular pathways interacting with chemoresistance in clear cell carcinoma. Oxidative stress induced by repeated hemorrhage induces greater susceptibility of endometriotic cells to DNA damage, and subsequent malignant transformation results in endometriosis-associated ovarian cancer. Molecular changes, including those in HNF-1β and checkpoint kinase 1 (Chk1), may be a manifestation of essential alterations in cell cycle regulation, detoxification and chemoresistance in clear cell carcinoma. Chk1 is a critical signal transducer in the cell cycle checkpoint machinery. DNA damage, in turn, increases persistent phosphorylation of Chk1 and induction of G2/M phase cell cycle arrest in cells overexpressing HNF-1β. HNF-1β deletion induces apoptosis, suggesting that enhanced levels of HNF-1β may be associated with chemoresistance. Targeted therapy with Chk1 inhibitors may be explored as a potential treatment modality for patients with clear cell carcinoma. This provides a novel direction for combination therapy, including targeting of Chk1, which may overcome drug resistance and improve treatment efficacy.

View Figures

View References

1	Bulun SE: Endometriosis. N Engl J Med. 360:268–279. 2009. View Article : Google Scholar : PubMed/NCBI
2	Dzatic-Smiljkovic O, Vasiljevic M, Djukic M, Vugdelic R and Vugdelic J: Frequency of ovarian endometriosis in epithelial ovarian cancer patients. Clin Exp Obstet Gynecol. 38:394–398. 2011.PubMed/NCBI
3	Abugo OO and Rifkind JM: Oxidation of hemoglobin and the enhancement produced by nitroblue tetrazolium. J Biol Chem. 269:24845–24853. 1994.PubMed/NCBI
4	Shikama K and Matsuoka A: Human haemoglobin: A new paradigm for oxygen binding involving two types of alphabeta contacts. Eur J Biochem. 270:4041–4051. 2003. View Article : Google Scholar : PubMed/NCBI
5	Polak G, Wertel I, Barczyński B, Kwaśniewski W, Bednarek W and Kotarski J: Increased levels of oxidative stress markers in the peritoneal fluid of women with endometriosis. Eur J Obstet Gynecol Reprod Biol. 168:187–190. 2013. View Article : Google Scholar : PubMed/NCBI
6	Reuter S, Gupta SC, Chaturvedi MM and Aggarwal BB: Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med. 49:1603–1616. 2010. View Article : Google Scholar : PubMed/NCBI
7	Mahalingaiah PK and Singh KP: Chronic oxidative stress increases growth and tumorigenic potential of MCF-7 breast cancer cells. PLoS One. 9:e873712014. View Article : Google Scholar : PubMed/NCBI
8	Akasaka J, Uekuri C, Shigetomi H, Koike M and Kobayashi H: Hepatocyte nuclear factor (HNF)-1β and its physiological importance in endometriosis. Biomed Rep. 1:13–17. 2013.PubMed/NCBI
9	Shigetomi H, Sudo T, Shimada K, Uekuri C, Tsuji Y, Kanayama S, Naruse K, Yamada Y, Konishi N and Kobayashi H: Inhibition of cell death and induction of G2 arrest accumulation in human ovarian clear cells by HNF-1β transcription factor: Chemosensitivity is regulated by checkpoint kinase CHK1. Int J Gynecol Cancer. 24:838–843. 2014. View Article : Google Scholar : PubMed/NCBI
10	Kobayashi H, Kajihara H, Yamada Y, Tanase Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, Yoshida S, Naruse K, et al: Risk of carcinoma in women with ovarian endometrioma. Front Biosci (Elite Ed). 3:529–539. 2011. View Article : Google Scholar : PubMed/NCBI
11	Liu C, Liu X, Janes J, Stapley R, Patel RP, Gladwin MT and Kim-Shapiro DB: Mechanism of faster NO scavenging by older stored red blood cells. Redox Biol. 2:211–219. 2014. View Article : Google Scholar : PubMed/NCBI
12	Cadet J, Delatour T, Douki T, Gasparutto D, Pouget JP, Ravanat JL and Sauvaigo S: Hydroxyl radicals and DNA base damage. Mutat Res. 424:9–21. 1999. View Article : Google Scholar : PubMed/NCBI
13	Wei H, Cai Q and Rahn RO: Inhibition of UV light- and Fenton reaction-induced oxidative DNA damage by the soybean isoflavone genistein. Carcinogenesis. 17:73–77. 1996. View Article : Google Scholar : PubMed/NCBI
14	Kobayashi H, Kajiwara H, Kanayama S, Yamada Y, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T and Oi H: Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review). Oncol Rep. 22:233–240. 2009.PubMed/NCBI
15	Xue X and Shah YM: Intestinal iron homeostasis and colon tumorigenesis. Nutrients. 5:2333–2351. 2013. View Article : Google Scholar : PubMed/NCBI
16	Toyokuni S: Mysterious link between iron overload and CDKN2A/2B. J Clin Biochem Nutr. 48:46–49. 2011. View Article : Google Scholar : PubMed/NCBI
17	Rolfs F, Huber M, Gruber F, Böhm F, Pfister HJ, Bochkov VN, Tschachler E, Dummer R, Hohl D, Schäfer M, et al: Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesis. Cancer Res. 73:3460–3469. 2013. View Article : Google Scholar : PubMed/NCBI
18	Yang Y, Zhang Y, Wu Q, Cui X, Lin Z, Liu S and Chen L: Clinical implications of high NQO1 expression in breast cancers. J Exp Clin Cancer Res. 33:142014. View Article : Google Scholar : PubMed/NCBI
19	Tanase Y, Yamada Y, Shigetomi H, Kajihara H, Oonogi A, Yoshizawa Y, Furukawa N, Haruta S, Yoshida S, Sado T, et al: Modulation of estrogenic action in clear cell carcinoma of the ovary (Review). Exp Ther Med. 3:18–24. 2012.PubMed/NCBI
20	Kajihara H, Yamada Y, Shigetomi H, Higashiura Y and Kobayashi H: The dichotomy in the histogenesis of endometriosis-associated ovarian cancer: Clear cell-type versus endometrioid-type adenocarcinoma. Int J Gynecol Pathol. 31:304–312. 2012. View Article : Google Scholar : PubMed/NCBI
21	Yamada Y, Shigetomi H, Onogi A, Haruta S, Kawaguchi R, Yoshida S, Furukawa N, Nagai A, Tanase Y, Tsunemi T, et al: Redox-active iron-induced oxidative stress in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer. 21:1200–1207. 2011.PubMed/NCBI
22	Itamochi H, Kigawa J, Akeshima R, Sato S, Kamazawa S, Takahashi M, Kanamori Y, Suzuki M, Ohwada M and Terakawa N: Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology. 62:349–353. 2002. View Article : Google Scholar : PubMed/NCBI
23	Pectasides D, Pectasides E, Psyrri A and Economopoulos T: Treatment issues in clear cell carcinoma of the ovary: A different entity? Oncologist. 11:1089–1094. 2006. View Article : Google Scholar : PubMed/NCBI
24	Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, Sakata M, Yamada Y, Oi H and Kobayashi H: Theoretical model of treatment strategies for clear cell carcinoma of the ovary: Focus on perspectives. Cancer Treat Rev. 35:608–615. 2009. View Article : Google Scholar : PubMed/NCBI
25	Mogami T, Yokota N, Asai-Sato M, Yamada R, Koizume S, Sakuma Y, Yoshihara M, Nakamura Y, Takano Y, Hirahara F, et al: Annexin A4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear cell adenocarcinoma cells. PLoS One. 8:e803592013. View Article : Google Scholar : PubMed/NCBI
26	Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ and Mok SC: Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res. 11:6880–6888. 2005. View Article : Google Scholar : PubMed/NCBI
27	Kajihara H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sado T, Oi H and Kobayashi H: Clear cell carcinoma of the ovary: Potential pathogenic mechanisms (Review). Oncol Rep. 23:1193–1203. 2010.PubMed/NCBI
28	Mandai M, Matsumura N, Baba T, Yamaguchi K, Hamanishi J and Konishi I: Ovarian clear cell carcinoma as a stress-responsive cancer: Influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Lett. 310:129–133. 2011. View Article : Google Scholar : PubMed/NCBI
29	Yamaguchi K, Huang Z, Matsumura N, Mandai M, Okamoto T, Baba T, Konishi I, Berchuck A and Murphy SK: Epigenetic determinants of ovarian clear cell carcinoma biology. Int J Cancer. 135:585–597. 2014. View Article : Google Scholar : PubMed/NCBI
30	Hecht JL, Kotsopoulos J, Hankinson SE and Tworoger SS: Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: Results from the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev. 18:1624–1630. 2009. View Article : Google Scholar : PubMed/NCBI
31	Iida Y, Aoki K, Asakura T, Ueda K, Yanaihara N, Takakura S, Yamada K, Okamoto A, Tanaka T and Ohkawa K: Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma. Int J Oncol. 40:2122–2130. 2012.PubMed/NCBI
32	Cuff J, Salari K, Clarke N, Esheba GE, Forster AD, Huang S, West RB, Higgins JP, Longacre TA and Pollack JR: Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis. PLoS One. 8:e745622013. View Article : Google Scholar : PubMed/NCBI
33	Dai Y and Grant S: New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res. 16:376–383. 2010. View Article : Google Scholar : PubMed/NCBI
34	Zharkov DO: Base excision DNA repair. Cell Mol Life Sci. 65:1544–1565. 2008. View Article : Google Scholar : PubMed/NCBI
35	Smith J, Tho LM, Xu N and Gillespie DA: The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 108:73–112. 2010.PubMed/NCBI
36	Reinhardt HC and Yaffe MB: Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol. 21:245–255. 2009. View Article : Google Scholar : PubMed/NCBI
37	Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 88:2584–2589. 2000. View Article : Google Scholar : PubMed/NCBI
38	Reed E, Yu JJ, Davies A, Gannon J and Armentrout SL: Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res. 9:5299–5305. 2003.PubMed/NCBI
39	Mao TL and Shih IeM: The roles of ARID1A in gynecologic cancer. J Gynecol Oncol. 24:376–381. 2013. View Article : Google Scholar : PubMed/NCBI
40	Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, Yasugi T, Taketani Y and Hirohashi S: Expression profiling in ovarian clear cell carcinoma: Identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 163:2503–2512. 2003. View Article : Google Scholar : PubMed/NCBI
41	Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Lockhart AC, Naughton MJ, Pluard TJ, et al: A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat. 137:483–492. 2013. View Article : Google Scholar : PubMed/NCBI
42	Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, et al: Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica. 96:1619–1626. 2011. View Article : Google Scholar : PubMed/NCBI
43	Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, et al: Clear cell carcinoma of the ovary: A retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 94:1369–1374. 2006. View Article : Google Scholar : PubMed/NCBI